Genetic polymorphisms in long noncoding RNA H19 are associated with susceptibility to breast cancer in Chinese population

Medicine (United States)

Volumn 95, Issue 7, 2016, Pages e2771-

  Xia, Zongjiang ^a   Yan, Rui ^b,c   Duan, Fujiao ^b   Song, Chunhua ^b,c   Wang, Peng ^b,c   Wang, Kaijuan ^b,c  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c Henan Key Laboratory of Tumor Epidemiology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LONG UNTRANSLATED RNA; RNA H19; H19 LONG NON-CODING RNA;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HAPLOTYPE MAP; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RESTRICTION SITE; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RISK;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; RNA, LONG NONCODING;

EID: 84959127680     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002771     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. Ca Cancer J Clin. 2011;61:69-90.
2. DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52-62.
3. Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol. 2014;15:e279-289.
4. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2:133-140.
5. Zhang B, Beeghly-Fadiel A, Long J, et al. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol. 2011;12:477-488.
6. Bradbury AR, Olopade OI. Genetic susceptibility to breast cancer. Rev Endocr Metab Disord. 2007;8:255-267.
7. Sapkota Y, Mackey JR, Lai R, et al. Assessing SNP-SNP Interactions among DNA repair, modification and metabolism related pathway genes in breast cancer susceptibility. PLoS One. 2013;8:e64896.
8. Bertone P, Stolc V, Royce TE, et al. Global identification of human transcribed sequences with genome tiling arrays. Science. 2004;306:2242-2246.
9. Mattick JS. The functional genomics of noncoding RNA. Science. 2005;309:1527-1528.
10. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071-1076.
11. Gu Y, Chen T, Li G, et al. LncRNAs: emerging biomarkers in gastric cancer. Future Oncol. 2015;11:2427-2441.
12. Zhao J, Liu Y, Zhang W, et al. Long non-coding RNA Linc00152 is involved in cell cycle arrest, apoptosis, epithelial to mesenchymal transition, cell migration and invasion in gastric cancer. Cell Cycle. 2015;14:1-12.
13. Sun H, Wang G, Peng Y, et al. H19 lncRNA mediates 17beta-estradiol-induced cell proliferation in MCF-7 breast cancer cells. Oncol Rep. 2015;33:3045-3052.
14. Xue Y, Gu DY, Ma GX, et al. Genetic variants in lncRNA HOTAIR are associated with risk of colorectal cancer. Mutagenesis. 2015;30:303-310.
15. Pan W, Liu L, Wei J, et al. A functional lncRNA HOTAIR genetic variant contributes to gastric cancer susceptibility. Mol Carcinog. 2015;55:90-96.
16. Li N, Zhou P, Zheng J, et al. A polymorphism rs12325489C > T in the LincRNA-ENST00000515084 exon was found to modulate breast cancer risk via GWAS-based association analyses. Plos One. 2014;9:e98251.
17. Wu HC, Zheng J, Deng JQ, et al. A genetic polymorphism in lincRNA-uc003opf.1 is associated with susceptibility to esophageal squamous cell carcinoma in Chinese populations. Carcinogenesis. 2013;34:2908-2917.
18. Brannan CI, Dees EC, Ingram RS, et al. The product of the H19 gene may function as an RNA. Mol Cell Biol. 1990;10:28-36.
19. Yoshimizu T, Miroglio A, Ripoche MA, et al. The H19 locus acts in vivo as a tumor suppressor. Proc Natl Acad Sci USA. 2008;105:12417-12422.
20. Zhang L, Yang F, Yuan JH, et al. Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis. 2013;34:577-586.
21. Matouk IJ, DeGroot N, Mezan S, et al. The H19 non-coding RNA Is essential for human tumor growth. Plos One. 2007;2:e845.
22. Yang C, Tang R, Ma X, et al. Tag SNPs in long non-coding RNA H19 contribute to susceptibility to gastric cancer in the Chinese Han population. Oncotarget. 2015;6:15311-15320.
23. Verhaegh GW, Verkleij L, Vermeulen SH, et al. Polymorphisms in the H19 gene and the risk of bladder cancer. Eur Urol. 2008;54:1118-1126.
24. Takai D, Gonzales FA, Tsai YC, et al. Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum Mol Genet. 2001;10:2619-2626.
25. Wilkin F, Paquette J, Ledru E, et al. H19 sense and antisense transgenes modify insulin-like growth factor-II mRNA levels. Eur J Biochem/FEBS. 2000;267:4020-4027.
26. Gao W, Zhu M, Wang H, et al. Association of polymorphisms in long non-coding RNA H19 with coronary artery disease risk in a Chinese population. Mutat Res. 2015;772:15-22.
27. Hewage AS, Jayanthiny P, Tennekoon KH, et al. H19 rs217727 genotype and IGF-1/intron-2 dinucleotide CT repeat polymorphism are independently associated with birth weight. Endocrine. 2015;48:1010-1012.
28. Verhaegh GW, Verkleij L, Vermeulen SHHM, et al. Polymorphisms in the H19 gene and the risk of bladder cancer. Eur Urol. 2008;54:1118-1126.
29. Adriaenssens E, Lottin S, Dugimont T, et al. Steroid hormones modulate H19 gene expression in both mammary gland and uterus. Oncogene. 1999;18:4460-4473.
30. Keniry A, Oxley D, Monnier P, et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and lgf1r. Nat Cell Biol. 2012;14:659-665.
31. Basak P, Chatterjee S, Weger S, et al. Estrogen regulates luminal progenitor cell differentiation through H19 gene expression. Endocr-Relat Cancer. 2015;22:505-517.
32. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002;296:2225-2229.
33. Akey J, Jin L, Xiong MM. Haplotypes vs single marker linkage disequilibrium tests: what do we gain? Eur J Hum Genet. 2001;9:291-300.
34. Colhoun HM, McKeigue PM, Smith GD. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361:865-872.
35. Ioannidis JPA, Ntzani EE, Trikalinos TA, et al. Replication validity of genetic association studies. Nat Genet. 2001;29:306-309.
36. Sterne JA, Davey Smith G. Sifting the evidence-what's wrong with significance tests? BMJ. 2001;322:226-231.